Indaptus Therapeutics, Inc. Assets, Noncurrent
Indaptus Therapeutics, Inc. (INDP) had Assets, Noncurrent of $401.06 thousand as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AssetsNoncurrent · last filed 2026-03-17
- 2025-09-30: Assets, Noncurrent $401.06K.
- 2025-06-30: Assets, Noncurrent $426.15K.
- 2025-03-31: Assets, Noncurrent $450.69K.
- 2024-12-31: Assets, Noncurrent $720.43K.
| Period end | Assets, Noncurrent | Assets, Noncurrent as first filed |
|---|---|---|
| 2025-09-30 | $401.06K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $426.15K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $450.69K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $720.43K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $610.38K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $633.36K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $655.85K 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $928.67K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $950.53K 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $971.95K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $992.93K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $819.56K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $859.32K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $786.63K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $166.84K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $189.37K 10-K · filed 2023-03-17 | |
| 2021-09-30 | $4.33K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.30M 10-Q · filed 2021-08-16 | |
| 2020-12-31 | $45.79K 10-K · filed 2022-03-21 | $5.93M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |